Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Context Therapeutics ( (CNTX) ) has shared an update.
On August 28, 2025, Context Therapeutics Inc. received an extension from Nasdaq until February 23, 2026, to comply with the Minimum Bid Price Rule, which requires a minimum closing bid price of $1.00 per share. The company had previously been notified of non-compliance on February 27, 2025, and is considering options such as a reverse stock split to meet the requirement, although there is no assurance of compliance by the deadline.
The most recent analyst rating on (CNTX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Context Therapeutics stock, see the CNTX Stock Forecast page.
Spark’s Take on CNTX Stock
According to Spark, TipRanks’ AI Analyst, CNTX is a Underperform.
Context Therapeutics has significant financial challenges, with no revenue and consistent losses, heavily weighing down its overall score. Technical analysis shows neutral market momentum, while valuation metrics highlight unprofitability. However, the recent initiation of a Phase 1 trial offers some hope for future growth. Collectively, these factors result in a low overall stock score, reflecting the company’s current financial instability and speculative potential.
To see Spark’s full report on CNTX stock, click here.
More about Context Therapeutics
Average Trading Volume: 229,301
Technical Sentiment Signal: Sell
Current Market Cap: $75.35M
Find detailed analytics on CNTX stock on TipRanks’ Stock Analysis page.